Biosimilars: Eight Is More Than Enough For FDA
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Eight pre-IND and IND applications for biosimilar products have been submitted to the Division of Therapeutic Proteins in CDER's Office of Biotechnology Products, according to division Director Amy Rosenberg.